Adalimumab, etanercept, infliximab,certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not  previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

Stevenson, Matt; Archer, Rachel; Tosh, Jon; Simpson, Emma; Everson-Hock, Emma; Stevens, John; Hernandez-Alava, Monica; Paisley, Suzy; Dickinson, Kath; Scott, David; Young, Adam; Wailoo, Allan

doi:10.3310/hta20350

An error occurred retrieving publication content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

Extended Research Article

Toolkit

View Award

Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young & Allan Wailoo.

Detailed Author information
Detailed Author information

Matt Stevenson ^1,^*, Rachel Archer ¹, Jon Tosh ¹, Emma Simpson ¹, Emma Everson-Hock ¹, John Stevens ¹, Monica Hernandez-Alava ¹, Suzy Paisley ¹, Kath Dickinson ¹, David Scott ², Adam Young ³, Allan Wailoo ¹

¹ School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
² Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK
³ Department of Rheumatology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK
^* Corresponding author Email: m.d.stevenson@sheffield.ac.uk

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Report Content

Full Report
Abstract
Plain English Summary
Plain Language Summary
Scientific Summary

The full text of this issue is available as a PDF document from the Toolkit section on this page.

Responses to this report

Response by Professor Matt Stevenson on 2 June 2021 at 9:51 AM
Report updated in 2021 and new results presented in NIHR131265
This report was updated in 2021 and should be read in conjunction with NIHR131265, related award - https://fundingawards.nihr.ac.uk/award/NIHR131265 New results were presented to the NICE Appraisal Committee after multiple changes had been made to the modelling previously considered by NICE. These changes included: 1) using the latest prices, associated with some interventions noting that some had considerably fallen in price, 2) acknowledging that patients with moderate RA would receive biologic therapy when they progressed to severe, and 3) only allowing rituximab and tocilizumab treatment in patients with severe RA. A description of the work is presented as an Appendix to the initial HTA monograph. However, the cost-effectiveness results are commercial-in-confidence and cannot be reported in public.

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors. Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

Enter response message*

Name (title, first name, last name)*

Occupation / Job title*

Affiliation / Employer*

Email*

Other authors
For example, if you are responding as a team or group. Please ensure you include full names and separate these using commas

Statement of competing interests
We believe that readers should be aware of any competing interests (conflicts of interest).
The International Committee of Medical Journal Editors (ICMJE) define competing interests as including: financial relationships with industry (for example through employment, consultancies, stock, ownership, honoraria, and expert testimony), either directly or through immediate family; personal relationships; academic competition; and intellectual passion.

If yes, please provide details below

Enter response title*

Enter CAPTCHA What is six multiplied by three?*

By submitting your response, you are stating that you agree to the terms & conditions

An error has occurred in processing the XML document